On November 4, 2025 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the European Patent Office (EPO) has communicated its intent to grant Genprex a patent for the use of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to continue bolstering our patent estate, which includes multiple patents for the use of REQORSA in combination with both PD-1 and PD-L1 antibodies across many markets," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. "This European patent will further strengthen our intellectual property portfolio and the patent protection around REQORSA in order to safeguard our gene therapy with target-specific combination therapy."
This patent will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore.
REQORSA is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. The Company believes REQORSA’s unique attributes position it to provide potential treatments that improve on these current therapies for patients with lung cancer and possibly other cancers.
According to Eurostat, in 2021, nearly a quarter of a million people died from lung cancer in the EU, accounting for almost a fifth of all cancer deaths and accounting for 4.3% of the total number of deaths. According to the European Commission, it is estimated that in the EU-27 countries in 2020, lung cancer accounted for 11.9% of all new cancer diagnoses (excluding non-melanoma skin cancers) and 20.4% of all deaths due to cancer. In addition, lung cancer was the fourth most frequently occurring cancer (after prostate, breast, and colorectal cancers) and the leading cause of cancer death.
According to data from GLOBOCAN 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4.62 million new cases and 3.55 million deaths by 2050.
(Press release, Genprex, NOV 4, 2025, View Source [SID1234659356])